BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 07:00PM GMT
Release Date Price: €39.4 (+1.03%)
Scott Puckhaber;Bank of America Merrill Lynch;Vice President
Equity Research,

All right. Welcome, everybody, to the afternoon session of the BofA Virtual Health Care Conference. I'm Scott Puckhaber, one of the biopharma analysts here at BofA. We're really thrilled to have BioXcel present with us today and have CEO Vimal Mehta with us. Also I have Geoff Meacham on the line as well.

So with that, I'll hand it over to Vimal for some initial prepared remarks, and then we'll get into the Q&A. So Vimal, you there?

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, Secretary & Director

Yes, I'm here. Good afternoon, everyone. I'm Dr. Vimal Mehta, Chief Executive Officer of BioXcel Therapeutics, a clinical-stage company utilizing artificial intelligence approaches to identify and advance novel opportunities in neuroscience and immuno-oncology.

I want to thank Geoff and Scott for organizing this conversation and providing us with another opportunity to stay in communication with our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot